Study S000632

Parallel Group Study to Evaluate the Efficacy and Safety of Exenatide Once-Weekly Injection Compared to Once-Daily Insulin in Type 2 Diabetes Mellitus Treated With Oral Antidiabetic(s)

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Included trial: extracted data ClinicalTrials.gov record

Registration

Registration: NCT00935532
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: NONE
Status: COMPLETED
Enrollment: 427
Start: 2009-07
Primary completion: 2010-09
Lead sponsor: AstraZeneca
Conditions: Type 2 Diabetes Mellitus
Interventions: DRUG:exenatide once weekly; DRUG:insulin glargine
Results posted: TRUE

Registered primary outcomes

Change in HbA1c From Baseline to Endpoint (Week 26) [Baseline, Week 26]

Linked records (2)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0013562	Safety and Efficacy of Exenatide Once Weekly in Participants with Type 2 Diabetes and Stage 2/3 Chronic Kidney Disease. Guja C, Diabetes therapy : research, treatment and education of diabetes and related disorders	2020	Other trial	PMID 32306296 DOI	cites ClinicalTrials.gov:NCT00935532; registry reference DERIVED:32306296
R0019328	Efficacy and safety profile of exenatide once weekly compared with insulin once daily in Japanese patients with type 2 diabetes treated with oral antidiabetes drug(s): results from a 26-week, randomized, open-label, parallel-group, multicenter, noninferiority study. Inagaki N, Clinical therapeutics	2012	Randomized trial	PMID 22884767 DOI	cites ClinicalTrials.gov:NCT00935532; registry reference DERIVED:22884767